SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Kosan BioSciences -- KOSN
An SI Board Since May 2001
Posts SubjectMarks Bans Symbol
933 40 0 KOSN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
508[17-DMAG Enhances tumor radiosensitivity & abrogation of the G(2)- and S-phatuck-12/10/2004
507KOS-953 (17-AAG) Shows Anticancer Activity in Preclinical Studies Reported at thFiloF-12/5/2004
50607:37 ET Kosan Biosciences NSCLC Phase II Trial Discontinued (KOSN) 6.55: The KOtom pope-11/23/2004
505Cell Cycle. 2004 Dec 30;3(12) [Epub ahead of print] Hsp90 Activation and Cell scaram(o)uche-11/14/2004
504Functional proteomic screens reveal an essential extracellular role for hsp90 innigel bates-11/14/2004
503Would this point towards a rationale for pursuing an antibody approach to HSP90 nigel bates-11/14/2004
502Welcome [Sign In] To track stocks & more, Register Financial News Enter mopgcw-10/28/2004
501[Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycintuck-10/27/2004
500Orphan Drug Designation Granted to Kosan's 17-AAG for the Treatment of Chronmopgcw-10/26/2004
499[Total synthesis of long DNA sequences] >>Published online before print Otuck-10/20/2004
498OT- Neutec's candida program: PR on latest clinical trial neutecpharma.comf_mcknuckles-10/5/2004
497[Kinetics and mechanism of degradation of epothilone-D: An experimental anticanctuck-10/3/2004
496Int J Cancer. 2004 Sep 28 [Epub ahead of print] Hsp90 inhibitors deplete key ascaram(o)uche-9/30/2004
495(Vernalis/Hsp90) Missed posting this back in August (jetlag?): <pre> nigel bates-9/17/2004
494eortc-nci-aacr...... woensdag 29 september 2004 Poster session: New drug targetscaram(o)uche-9/2/2004
493[PK/PD of 17DMAG in mice with breast cancer xenografts] >>Cancer Chemothetuck-9/1/2004
492On Thursday, 9/30, N. Zaffaroni will be presenting a paper at the EORTC meeting tuck-8/31/2004
491Kosan Announces Senior Management Changes Friday August 13, 9:30 am ET HAYWARDmopgcw-8/13/2004
490Kosan Reports Second Quarter and Six Month Financial Results PR Newswire, Tmopgcw-7/29/2004
489Kosan Initiates Its Second KOS-862 Phase Ib Chemotherapy Combination Trial Mondanigel bates-7/26/2004
488Neutec/Hsp90... Can't find anything published, but there is this from the fnigel bates-7/23/2004
487[Antiangiogenic Properties of DMAG, An Orally Bioavailable Heat Shock Protein 90tuck-7/21/2004
486commentwire.com Kosan Biosciences: some hope for metastatic melanoma Kosan Bioscaram(o)uche-7/21/2004
485Kosan's Second-Generation Hsp90 Inhibitor, DMAG, Enters Clinic Wednesday Julnigel bates-7/21/2004
484Kosan Announces Initiation of Phase II Trial of 17-AAG Monday July 19, 7:30 am Enigel bates-7/19/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News